About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ambrx Appoints Olivia Ware and Katrin Rupalla to its Board of Directors

By: via Business Wire

Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointments of Olivia C. Ware and Katrin Rupalla, Ph.D., to its Board of Directors.

“We are thrilled to have both Olivia and Katrin join the Ambrx team at a such a pivotal time in the company’s history,” said Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx. “Olivia brings invaluable experience across all stages of the product development cycle, from pharmaceutical drug development and commercialization to healthcare management. Katrin has extensive experience in global regulatory strategy and drug candidate development. I look forward to benefiting from Olivia and Katrin’s counsel in the months and years to come, as we advance our clinical development pipeline, including our lead asset ARX788.”

“I am delighted to be appointed to Ambrx’s Board and joining what I believe to be a very talented and highly capable team,” said Ms. Ware. “I hope to leverage my clinical and commercial experience as we collectively seek to advance an innovative pipeline of drugs from Ambrx’s technology platform.”

Ms. Ware joins Ambrx with more than 20 years of pharmaceutical drug development, commercialization and healthcare management experience, with a history of successful commercial drug launches including Rituxan®, Herceptin®, Avastin® and Lucentis®. In addition to drug development, Ms. Ware also has experience in developing managed care, pricing and contract strategy, developing marketing programs for field-based sales teams, and establishing, growing and optimizing organizations for long-term success. Previously, Ms. Ware was the Senior Vice President, BTK Franchise Head at Principia Biopharma Inc., where she was responsible for developing portfolio strategy for the company’s three BTKi molecules. Prior to that, she served as Senior Vice President, U.S. Market and Franchise Development at Proteus Digital Health, Inc., was Chief Commercial Officer at CytRx, Inc., and held various leadership roles at Genentech, Inc.

Ms. Ware graduated from Davidson College and received her MBA from the University of North Carolina at Chapel Hill. She is now President of Davidson College Board of Visitors and member of the Davidson Board of Trustees.

“I’m excited to be joining Ambrx, especially given the recent clinical progress the company has made in both China and the United States,” said Dr. Rupalla. “I look forward to assisting the company’s regulatory affairs and drug development efforts in both countries, so that we can together progress Ambrx’s innovative Engineered Precision Biologics to create more precise therapeutic treatments to address significant unmet needs.”

Dr. Rupalla has more than 25 years’ experience in the pharmaceutical industry at a global scale serving the United States, Europe and China. Currently, Dr. Rupalla serves as Senior Vice President of Regulatory Affairs, R&D Quality and Medical Information at Lundbeck. Prior to joining Lundbeck, she spent several years at Bristol Myers Squibb in various roles in drug development and regulatory affairs including as Head Development BMS in China, Vice President of European Union Regulatory Sciences, and Vice President of Oncology Global Regulatory Sciences. Dr. Rupalla has spent her career as an executive in global regulatory affairs at various other companies including Celgene, Roche, and Merck. Presently, she is a non-executive independent director at 4D Pharma PLC and iQure Pharma Inc.

Dr. Rupalla received a Master of Science in Pharmacy and a Ph.D. in CNS pharmacology from Philipps University of Marburg, Germany. She also has an MBA from Jones International University, CO, USA.

About Ambrx

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs optimized for efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology. For additional information, please visit www.ambrx.com.

Contacts

More News

View More
Could Target’s Week of Discounts Come Full Circle for Investors?
Via MarketBeat
Topics Economy
Tickers AAPL GE TGT WMT
3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings
Via MarketBeat
Tickers SFM
Bassett Furniture: Buy Now, Sit Back, and Collect Dividends
Via MarketBeat
Tickers BSET ETD HVT
AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon
Via MarketBeat
Tickers ASTS JOBY RGTI T VOD VZ
Catch the Next Bitcoin Rally With These 3 ETFs
Via MarketBeat
Topics ETFs
Tickers BITQ FBTC IBIT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.